AIDS

• Overview
  
• Treatment

Bacterial Vaginosis

• Overview
  
• Treatment

Cervical Dysplasia

• Overview
  
• Treatment

  
  Chlamydia
  
  

  • Overview
    
  • Treatment

  
  Condyloma Acuminata
  
  

  • Overview
    
  • Treatment

  
  Genital Herpes
  
  

  • Overview
    
  • Treatment

  
  Gonorrhea
  
  

  • Overview
    
  • Treatment

  
  Hepatitis
  
  

  • Overview
    
  • Treatment

  
  Pelvic Inflammatory Disease
  
  

  • Overview
    
  • Treatment

  
  Syphilis
  
  

  • Overview
    
  • Treatment

  
  Toxic Shock Syndrome
  
  

  • Overview
    
  • Treatment

  
  Yeast Infections
  
  

  • Overview
    
  • Treatment

  
  
  Market Size and Growth

  
  Geographical Market Analysis

  
  Research and Development

  
  Competitive Market

Chapter Six: Hormone-Related Disorders

Overview


Contraception



• Overview
  
• Treatment


Endometriosis



• Overview
  
• Treatment


Fibroids



• Overview
  
• Treatment


Infertility



• Overview
  
• Treatment


Menopause



• Overview
  
• Treatment


Menstrual Disorders



• Amenorrhea
  
• Dysmenorrhea


Sexual Dysfunction



• Overview
  
• Treatment


Market Size and Growth


Geographical Market Analysis


Research and Development


Competitive Market

Chapter Seven: Osteoporosis

• Overview
  Market Size and Growth
  Geographical Market Analysis
  Research and Development
  Competitive Market

Chapter Eight: Urinary Bladder Disorders

Overview


Cystitis



• Overview
  
• Treatment


Incontinence



• Overview
  
• Treatment
  
• Alternative Treatments


Interstitial Cystitis



• Overview
  
• Treatment


Market Size and Growth


Geographical Market Analysis


Research and Development


Competitive Market

Chapter Nine: Issues and Trends

• 2003 Budget Increases for Women’s Health Issues
  
• Women’s Health Initiative
  
• What Now? Guidance for the Industry
  
• Perimenopausal Use of Contraceptives
  
• Fosamax Patents Void in European Market
  
• Insurance Coverage for Contraceptives
  
• HPV Vaccine
  
• Foreign Girls and Young Women and HIV
  
• Oral Contraceptives in Japan
  
• Ovarian Cancer Test
  
• Immunotherapies in Ovarian Cancer
  
• New Pap Test Screening Guidelines
  
• Estrogen Labeling
  
• New Uterine Fibroid Treatment
  
• Inequality in Clinical Testing of Drugs
  
• Testing for Predisposition to Cancer
  
• Osteoporosis Drug Opportunities in Asia

Chapter Ten: World Market Summary

• Overview
  
• Total Market Size and Forecast
  
• Market Analysis

Chapter Eleven: Competitor Profiles

• Industry Structure and Participants
  
• Akzo Nobel NV (Organon)
  
• Amgen, Inc.
  
• AstraZeneca PLC
  
• Aventis
  
• Barr Laboratories, Inc.
  
• Bristol-Myers Squibb Company
  
• Eli Lilly and Company
  
• GlaxoSmithKline
  
• Johnson & Johnson
  
• Merck & Company, Inc.
  
• Novartis International AG
  
• Pfizer, Inc.
  
• Pharmacia Corporation
  
• Procter & Gamble Company
  
• Roche
  
• Schering AG
  
• Serono International S.A.
  
• Wyeth

Appendix: Company Directory

List of Exhibits

• Table 1-1: The Worldwide Market for Women’s Healthcare, Revenues by
  Segment, 1997-2007
  
• Figure 1-1: The Market for Women’s Healthcare Revenues by
  Segment 1997-2007
  
  
• Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2000
  
• Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2000 (Difference, in Years, between Females and Males)
  
• Table 2-2: World Population Growth, by Total World Population and Selected Country or Regions and Selected Characteristics
  
• Figure 2-2: World Population Growth by Sex 2000, 2002, 2010, 2020, 2025
  
• Figure 2-3: United States Population Growth by
  Sex 2000, 2002, 2010, 2020, 2025
  
• Figure 2-4: Five Major European Countries* Population Growth by
  Sex 2000, 2002, 2010, 2020, 2025
  
• Figure 2-5: Japan Population Growth by Sex 2000, 2002, 2010, 2020, 2025
  
• Table 2-3: World Female Population Growth by Selected Country or
  Regions and Selected Age Group
  
• Figure 2-6: World Female Population Growth by Selected Age
  Group 2000, 2002, 2010, 2020, 2025
  
• Figure 2-7: United States Female Population Growth by Selected Age
  Group 2000, 2002, 2010, 2020, 2025
  
• Figure 2-8: Five Major European Countries Female Population Growth by
  Selected Age Group 2000, 2002, 2010, 2020, 2025
  
• Figure 2-9: Japan Female Population Growth by Selected Age Group 2000, 2002, 2010, 2020, 2025
  
• Table 2-4: Estimated Female Prevalence of Autoimmune Diseases by Type and Geographical Distribution
  
• Table 2-5: Estimated Incidence of Female Cancers and Mortality by Type and Geographical Distribution
  
• Table 2-6: Estimated Female Incidence and Prevalence Gynecological and
  Sexually Transmitted Diseases by Type and Geographical Distribution
  
• Table 2-7: Gynecological and Sexually Transmitted Diseases Related
  Epidemiologic Data
  
• Table 2-8: Estimated World and U.S. Female Incidence and Prevalence of
  Hormone-Related Disorders and Indications by Type
  
• Table 2-9: Estimated World and U.S. Contraceptive Use by Method
  
• Table 2-10: Estimated Female Prevalence of Osteoporosis by Type and
  Geographical Distribution
  
• Table 2-11: Estimated Female Incidence and Prevalence of Urinary Bladder Disorders by Type and Geographical Distribution
  
• Table 2-12: Estimated Female Statistics Concerning Lifestyle Patterns Contributing to Disease by Type of Behavior and Geographical Distribution
  
  
• Table 3-1: The World Market for Autoimmune Disease Drugs for Women by
  Type 1997-2007
  
• Figure 3-1: The World Market for Autoimmune Disease Drugs for Women
  Revenues by Type 1997-2007
  
• Table 3-2: The World Market for Autoimmune Disease Drugs for Women
  Market Share by Type 1997-2007
  
• Figure 3-2: The World Market for Autoimmune Disease Drugs for Women
  Share by Type 2002 & 2007
  
• Table 3-3: The World Market for Autoimmune Disease Drugs for Women
  Revenues by Geographical Region 1997-2007
  
• Table 3-4: The World Market for Autoimmune Disease Drugs for Women
  Share by Geographical Region 1997-2007
  
• Figure 3-3: The World Market for Autoimmune Disease Drugs for Women
  Share by Geographic Region 2002 and 2007
  
• Table 3-5: Products in Development for Selected Autoimmune Diseases 2002
  
• Table 3-6: The World Market for Autoimmune Disease Drugs for Women
  Revenues and Market Share by Supplier 2002
  
• Figure 3-4: The World Market for Autoimmune Disease Drugs for Women
  Market Share by Leading Supplier 2002
  
  
• Table 4-1: The World Market for Cancer Drugs for Women by
  Type 1997-2007
  
• Figure 4-1: The World Market for Cancer Drugs for Women Revenues by
  Type 1997-2007
  
• Table 4-2: The World Market for Cancer Drugs for Women Market Share by
  Type 1997-2007
  
• Figure 4-2: The World Market for Cancer Drugs for Women Share by
  Type 2002 and 2007
  
• Table 4-3: The World Market for Cancer Drugs for Women Revenues by Geographical Region 1997-2007
  
• Table 4-4: The World Market for Cancer Drugs for Women Share by
  Geographical Region 1997-2007
  
• Figure 4-3: The World Market for Cancer Drugs for Women Share
  Percentage 2002 and 2007
  
• Table 4-5: Products in Development for Women’s Cancers
  
• Table 4-6: The World Market for Cancer Drugs for Women Revenues and
  Market Share by Supplier 2002
  
• Figure 4-4: The World Market for Cancer Drugs for Women Market Share by Leading Supplier 2002
  
  
• Table 5-1: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women by Type 1997-2007
  
• Figure 5-1: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Type 1997-2007
  
• Table 5-2: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women, Market Share by Type 1997-2007
  
• Figure 5-2: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Type 2002 and 2007
  
• Table 5-3: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Geographical
  Region 1997-2007
  
• Table 5-4: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Geographical Region 1997-2007
  
• Figure 5-3: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Geographic
  Region 2002 and 2007
  
• Table 5-5: Products in Development for Women’s Gynecological Infections and Sexually Transmitted Diseases
  
• Table 5-6: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues and Market Share by
  Supplier 2002
  
• Figure 5-4: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Market Share by Leading Supplier 2002
  
  
• Table 6-1: Selected Oral Contraceptives Available 2002
  
• Table 6-2: Selected Hormone Replacement Therapies
  
• Table 6-3: The World Market for Hormone-Related Disorder Drugs for
  Women by Type 1997-2007
  
• Figure 6-1: The World Market for Hormone-Related Disorder Drugs for
  Women by Type 1997-2007
  
• Table 6-4: The World Market for Hormone-Related Disorder Drugs for
  Women Market Share by Type 1997-2007
  
• Figure 6-2: The World Market for Hormone-related Disorder Drugs for
  Women Share by Type 2002 and 2007
  
• Table 6-5: The World Market for Hormone-Related Disorder Drugs for
  Women Revenues by Geographical Region 1997-2007
  
• Table 6-6: The World Market for Hormone-Related Disorder Drugs for
  Women Share by Geographical Region 1997-2007
  
• Figure 6-3: The World Market for Hormone-Related Disorder Drugs for
  Women Share by Geographic Region 2002 and 2007
  
• Table 6-7: Hormonal Preparations in Research and Development for Women
  
• Table 6-8: The World Market for Hormone-Related Disorder Drugs for
  Women Revenues and Market Share by Supplier 2002
  
• Figure 6-4: The World Market for Hormone-Related Disorder Drugs for
  Women Market Share by Leading Supplier 2002
  
  
• Table 7-1: The World Market for Osteoporosis Drugs for Women
  Revenues by Type 1997-2007
  
• Figure 7-1: The World Market for Osteoporosis Drugs for Women
  Revenues by Type 1997-2007
  
• Table 7-2: The World Market for Osteoporosis Drugs for Women, Market
  Share by Type 1997-2007
  
• Figure 7-2: The World Market for Osteoporosis Drugs for Women Share by
  Type 2002 and 2003
  
• Table 7-3: The World Market for Osteoporosis Drugs for Women Revenues by Geographical Region 1997-2007
  
• Table 7-4: The World Market for Osteoporosis Drugs for Women Share by Geographical Region 1997-2007
  
• Figure 7-3: The World Market for Osteoporosis Drugs for Women Share by Geographic Region 2002 and 2007
  
• Table 7-5: Products in Development for Osteoporosis
  
• Table 7-6: The World Market for Osteoporosis Drugs for Women Revenues and Market Share by Supplier 2002
  
• Figure 7-4: The World Market for Osteoporosis Drugs for Women Market
  Share by Leading Supplier 2002
  
  
• Table 8-1: Medications That Can Affect Urination
  
• Table 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Revneues by Type 1997-2007
  
• Figure 8-1: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type 1997-2007
  
• Table 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Market Share by Type 1997-2007
  
• Figure 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Share by Type 2002 and 2007
  
• Table 8-4: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Geographical Region 1997-2007
  
• Table 8-5: The World Market for Urinary Bladder Disorder Drugs for Women Share by Geographical Region 1997-2007
  
• Figure 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Share by Geographic Region 2002 and 2007
  
• Table 8-6: Products in Development for Urinary Disorders
  
• Table 8-7: The World Market for Urinary Bladder Disorder Drugs for Women Revenues and Market Share by Supplier 2002
  
• Figure 8-4: The World Market for Urinary Bladder Disorder Drugs for Women Market Share by Leading Supplier 2002
  
  
• Table 10-1: The Worldwide Market for Women’s Healthcare, Revenues by
  Segment, 1997-2007
  
• Figure 10-1: The Market for Women’s Healthcare Revenues by
  Segment 1997-2007
  
• Table 10-2: The Market for Women’s Healthcare Market Share by
  Segment 1997-2007
  
• Figure 10-2: The Market for Women’s Healthcare Market Share by
  Type 2002 and 2007
  
• Table 10-3: The Market for Women’s Healthcare Revenues and Segments of Participation by Leading Market Participants 2002

Abstract

Scope and Methodology

For this study, the worldwide prescription drug market for women’s health is discussed in total manufacturers’ revenues for the following product categories:

• Autoimmune diseases
• Cancer
• Gynecological and Sexually Transmitted Diseases
• Hormones
• Osteoporosis
• Urinary Disorders

The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 62 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

All market data are presented at the manufacturers’ level in current U.S dollars. The base year for data was 2002. Historical data are provided for each of the years 1997 through 2002, and forecast data are provided for each of the years 2003 through 2007. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2002 base year.

Get Full Details About This Report >>